Researchers writing in mBio have published a multi-omics analysis of fungal balls, the dense aspergillomas that form inside the lungs of patients with chronic pulmonary aspergillosis. The study, led by Liu and colleagues, profiled microbiome composition and metabolic activity inside the lesions and identified patterns of microbial dynamics and metabolic adaptation that may help explain why the disease persists despite antifungal therapy.
Chronic pulmonary aspergillosis is the long-term, progressive form of Aspergillus infection in the lungs, distinct from the acute invasive disease seen in immunocompromised patients. It typically develops in people with underlying lung damage from tuberculosis, COPD, or other chronic conditions, and treatment is often prolonged and incomplete.
The multi-omics approach combines genetic, transcriptomic, and metabolic data to build a richer picture of what is happening inside the lesion than any single technique could produce. The authors argue that understanding the microbial community and metabolic context of fungal balls could open new treatment angles beyond the existing antifungal drug classes.